Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SUM159PT Taxol
1.0
Chemo
Chemotherapy
 -0.1266 0.52530
SUM159PT Topotecan
0.0010833
Topo I
Chemotherapy
 0.9874 -0.01573
SUM159PT Topotecan
0.0033333
Topo I
Chemotherapy
 0.9525 -0.01951
SUM159PT Topotecan
0.01
Topo I
Chemotherapy
 0.8336 -0.02132
SUM159PT Topotecan
0.031667
Topo I
Chemotherapy
 0.1801 0.29604
SUM159PT Topotecan
0.1
Topo I
Chemotherapy
 -0.0008 0.30768
SUM159PT Topotecan
0.31623
Topo I
Chemotherapy
 -0.0880 0.43103
SUM159PT Topotecan
1.0
Topo I
Chemotherapy
 -0.2109 0.59200
SUM159PT Topotecan
3.1623
Topo I
Chemotherapy
 -0.2888 0.70367
SUM159PT Topotecan
10.0
Topo I
Chemotherapy
 -0.3284 0.72256
SUM159PT Etoposide
0.0010833
Topo II
Chemotherapy
 0.9995 -0.02084
SUM159PT Etoposide
0.0033333
Topo II
Chemotherapy
 1.0069 -0.02190
SUM159PT Etoposide
0.01
Topo II
Chemotherapy
 1.0149 -0.02439
SUM159PT Etoposide
0.031667
Topo II
Chemotherapy
 0.9850 -0.01659
SUM159PT Etoposide
0.1
Topo II
Chemotherapy
 0.9198 -0.02101
SUM159PT Etoposide
0.31623
Topo II
Chemotherapy
 0.6414 0.06610
SUM159PT Etoposide
1.0
Topo II
Chemotherapy
 0.0979 0.43217
SUM159PT Etoposide
3.1623
Topo II
Chemotherapy
 -0.0537 0.37964
SUM159PT Etoposide
10.0
Topo II
Chemotherapy
 -0.1489 0.47690
SUM159PT Dasatinib
0.001
BCR/ABL
MAPK/nRTK
 0.9766 0.00610
SUM159PT Dasatinib
0.0031623
BCR/ABL
MAPK/nRTK
 0.9845 0.00893
SUM159PT Dasatinib
0.01
BCR/ABL
MAPK/nRTK
 0.9702 0.00142
SUM159PT Dasatinib
0.031623
BCR/ABL
MAPK/nRTK
 0.9754 0.00154
SUM159PT Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 0.8433 -0.00255
SUM159PT Dasatinib
0.31623
BCR/ABL
MAPK/nRTK
 0.6907 0.00112